المؤلفون: Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Lihong Liu, Guohua Yu, Yu Hu, Zheng Zhao, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Xiaoping Jin, Min Zhao, Baiyong Li, Yu Xia, Jun Zhu

المصدر: Frontiers in Oncology, Vol 12 (2022)

مصطلحات موضوعية: IgG1 anti-PD-1 antibody, penpulimab, classical Hodgkin lymphoma, efficacy, safety, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.925236/full; https://doaj.org/toc/2234-943X

URL الوصول: https://doaj.org/article/eed88d01c74342fbb542fea4869a544f

المؤلفون: Zhaoliang Huang, Xinghua Pang, Tingting Zhong, Tailong Qu, Na Chen, Shun Ma, Xinrong He, Dennis Xia, Max Wang, Michelle Xia, Baiyong Li

المصدر: Frontiers in Immunology, Vol 13 (2022)

مصطلحات موضوعية: IgG1 anti-PD-1 antibody, Fc engineering, penpulimab, binding kinetics, immune-related adverse events, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2022.924542/full; https://doaj.org/toc/1664-3224

URL الوصول: https://doaj.org/article/ac47a7c60d1f4502a8af848e72115466

المؤلفون: Zhaoliang Huang, Xinghua Pang, Tingting Zhong, Tailong Qu, Na Chen, Shun Ma, Xinrong He, Dennis Xia, Max Wang, Michelle Xia, Baiyong Li

مصطلحات موضوعية: Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, IgG1 anti-PD-1 antibody, Fc engineering, penpulimab, binding kinetics, immune-related adverse events

Relation: https://figshare.com/articles/figure/Image_3_Penpulimab_an_Fc-Engineered_IgG1_Anti-PD-1_Antibody_With_Improved_Efficacy_and_Low_Incidence_of_Immune-Related_Adverse_Events_tif/20161487

الاتاحة: https://doi.org/10.3389/fimmu.2022.924542.s004
https://figshare.com/articles/figure/Image_3_Penpulimab_an_Fc-Engineered_IgG1_Anti-PD-1_Antibody_With_Improved_Efficacy_and_Low_Incidence_of_Immune-Related_Adverse_Events_tif/20161487

المؤلفون: Zhaoliang Huang, Xinghua Pang, Tingting Zhong, Tailong Qu, Na Chen, Shun Ma, Xinrong He, Dennis Xia, Max Wang, Michelle Xia, Baiyong Li

مصطلحات موضوعية: Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, IgG1 anti-PD-1 antibody, Fc engineering, penpulimab, binding kinetics, immune-related adverse events

Relation: https://figshare.com/articles/dataset/DataSheet_1_Penpulimab_an_Fc-Engineered_IgG1_Anti-PD-1_Antibody_With_Improved_Efficacy_and_Low_Incidence_of_Immune-Related_Adverse_Events_docx/20161472

الاتاحة: https://doi.org/10.3389/fimmu.2022.924542.s001
https://figshare.com/articles/dataset/DataSheet_1_Penpulimab_an_Fc-Engineered_IgG1_Anti-PD-1_Antibody_With_Improved_Efficacy_and_Low_Incidence_of_Immune-Related_Adverse_Events_docx/20161472

المؤلفون: Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Lihong Liu, Guohua Yu, Yu Hu, Zheng Zhao, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Xiaoping Jin, Min Zhao, Baiyong Li, Yu Xia, Jun Zhu

مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, IgG1 anti-PD-1 antibody, penpulimab, classical Hodgkin lymphoma, efficacy, safety

Relation: https://figshare.com/articles/dataset/DataSheet_1_Penpulimab_for_Relapsed_or_Refractory_Classical_Hodgkin_Lymphoma_A_Multicenter_Single-Arm_Pivotal_Phase_I_II_Trial_AK105-201_docx/20251701

الاتاحة: https://doi.org/10.3389/fonc.2022.925236.s001
https://figshare.com/articles/dataset/DataSheet_1_Penpulimab_for_Relapsed_or_Refractory_Classical_Hodgkin_Lymphoma_A_Multicenter_Single-Arm_Pivotal_Phase_I_II_Trial_AK105-201_docx/20251701

المؤلفون: Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Lihong Liu, Guohua Yu, Yu Hu, Zheng Zhao, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Xiaoping Jin, Min Zhao, Baiyong Li, Yu Xia, Jun Zhu

مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, IgG1 anti-PD-1 antibody, penpulimab, classical Hodgkin lymphoma, efficacy, safety

Relation: https://figshare.com/articles/dataset/Table_1_Penpulimab_for_Relapsed_or_Refractory_Classical_Hodgkin_Lymphoma_A_Multicenter_Single-Arm_Pivotal_Phase_I_II_Trial_AK105-201_docx/20251710

الاتاحة: https://doi.org/10.3389/fonc.2022.925236.s004
https://figshare.com/articles/dataset/Table_1_Penpulimab_for_Relapsed_or_Refractory_Classical_Hodgkin_Lymphoma_A_Multicenter_Single-Arm_Pivotal_Phase_I_II_Trial_AK105-201_docx/20251710

المؤلفون: Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Lihong Liu, Guohua Yu, Yu Hu, Zheng Zhao, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Xiaoping Jin, Min Zhao, Baiyong Li, Yu Xia, Jun Zhu

مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, IgG1 anti-PD-1 antibody, penpulimab, classical Hodgkin lymphoma, efficacy, safety

Relation: https://figshare.com/articles/figure/Image_1_Penpulimab_for_Relapsed_or_Refractory_Classical_Hodgkin_Lymphoma_A_Multicenter_Single-Arm_Pivotal_Phase_I_II_Trial_AK105-201_tiff/20251704

الاتاحة: https://doi.org/10.3389/fonc.2022.925236.s002
https://figshare.com/articles/figure/Image_1_Penpulimab_for_Relapsed_or_Refractory_Classical_Hodgkin_Lymphoma_A_Multicenter_Single-Arm_Pivotal_Phase_I_II_Trial_AK105-201_tiff/20251704